Showing results (261-270 of 313) with videos related to

Sort By:
Pageof 32
Journal of Medical Primatology|July 1, 2015
Successful pharmaceutical-grade streptozotocin (STZ)-induced hyperglycemia in a conscious tethered baboon (Papio hamadryas) modelPatrice A Frost, Shuyuan Chen, Marguerite J Mezzles, et al.
Diabetes Care|January 11, 2024
Longitudinal Effects of Glucose-Lowering Medications on β-Cell Responses and Insulin Sensitivity in Type 2 Diabetes: The GRADE Randomized Clinical TrialNeda Rasouli, Naji Younes, Alokananda Ghosh, et al.
The Journal of Clinical Endocrinology and Metabolism|March 17, 2016
Diabetes Incidence and Glucose Tolerance after Termination of Pioglitazone Therapy: Results from ACT NOWDevjit Tripathy, Dawn C Schwenke, MaryAnn Banerji, et al.
Diabetes Care|April 8, 2014
Baseline adiponectin levels do not influence the response to pioglitazone in ACT NOWDevjit Tripathy, Stephen C Clement, Dawn C Schwenke, et al.
Diabetes|July 19, 2012
Fat-specific DsbA-L overexpression promotes adiponectin multimerization and protects mice from diet-induced obesity and insulin resistanceMeilian Liu, Ruihua Xiang, Sarah Ann Wilk, et al.
Diabetes|June 24, 2021
Adiponectin Alleviates Diet-Induced Inflammation in the Liver by Suppressing MCP-1 Expression and Macrophage InfiltrationJiyoon Ryu, Jason T Hadley, Zhi Li, et al.
Diabetes|July 19, 2013
Prevention of diabetes with pioglitazone in ACT NOW: physiologic correlatesRalph A Defronzo, Devjit Tripathy, Dawn C Schwenke, et al.
Diabetes Care|September 25, 2013
Prediction of diabetes based on baseline metabolic characteristics in individuals at high riskRalph A Defronzo, Devjit Tripathy, Dawn C Schwenke, et al.
Age (Dordrecht, Netherlands)|September 3, 2016
Pioglitazone is equally effective for diabetes prevention in older versus younger adults with impaired glucose toleranceSara E Espinoza, Chen-Pin Wang, Devjit Tripathy, et al.
BMJ Open|July 16, 2024
Study protocol for a prospective, multicentre study of hypercortisolism in patients with difficult-to-control type 2 diabetes (CATALYST): prevalence and treatment with mifepristoneRalph A DeFronzo, Richard J Auchus, Irina Bancos, et al.
Pageof 32